Targeted Therapy Global Market Report 2024

The targeted therapy market size has grown strongly in recent years. It will grow from $97.72 billion in 2023 to $105.06 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The expansion observed during the historic period can be attributed to several factors, including advancements in molecular biology, the rising incidence of cancer, the trend towards personalized medicine, and supportive regulatory frameworks such as FDA approvals. These elements collectively contributed to the growth and development of the relevant sectors.

The targeted therapy market size is expected to see strong growth in the next few years. It will grow to $140.77 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of oncology research, an increased demand for precision medicine, the emergence of immunotherapies, a growing investment in biopharmaceuticals, and heightened patient awareness and advocacy. Major trends expected in the forecast period involve the integration of artificial intelligence (AI) in drug discovery, greater patient advocacy and involvement in treatment decisions, an expansion of companion diagnostics, regulatory support for expedited approvals, and a notable increase in investments in biotechnology and pharmaceuticals.

The escalating prevalence of cancer, characterized by the uncontrolled division of aberrant cells that can invade surrounding tissues, is a pivotal driver for the heightened demand in the targeted therapy market. Targeted therapy, a treatment approach aimed at disrupting signals promoting cancer cell growth or triggering self-destruction signals, utilizes medications designed to specifically target genes and proteins supporting cancer cell survival. For example, in September 2021, the National Cancer Institute, a US-based government organization under the National Institutes of Health, reported a notable 43% increase in new cancer cases, reaching 1,806,590 registrations compared to the previous year. This surge in cancer cases is a key factor propelling the growth of the targeted therapy market.

The anticipated growth is expected to be bolstered by increasing government initiatives and funding. Government initiatives and funding encompass actions and financial support provided by government agencies across various sectors, including healthcare, science, technology, and education. Such support plays a crucial role in advancing targeted therapies, with a focus on research and development in precision medicine contributing to the commercial expansion of adapted therapies. In November 2023, the National Center for Science and Engineering Statistics, a US-based agency, reported a 5.2% increase in expenditures on research and experimental development, reaching $2.644 billion compared to the 2021 expenditures of $2.513 billion. This financial backing underscores the role of government support in driving the growth of the targeted therapy market.

Major companies in the targeted therapy market are actively engaged in developing innovative technological solutions to enhance their market position. For instance, in March 2022, Novartis AG, a Swiss multinational pharmaceutical corporation, introduced Pluvicto, the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer (mCRPC). Pluvicto combines a therapeutic radioisotope with a targeted chemical, representing a significant advancement in targeted cancer therapy. By binding to specific cells, including prostate cancer cells expressing the transmembrane protein PSMA, Pluvicto's radioisotope induces energy emissions that damage target cells and adjacent ones, impeding replication and potentially leading to cell death.

Companies in the targeted therapy market are also prioritizing strategic partnerships to enhance service offerings. One such example is Shine Technologies, a US-based pharmaceutical company specializing in radioactive isotopes, which partnered with Curadh MTR Inc. in September 2023. Curadh MTR Inc. focuses on advancing molecularly targeted radiation therapies for solid tumors. This collaboration aims to leverage radioisotopes' potential to precisely target and eliminate cancer cells, providing new prospects for patients and reshaping the landscape of cancer treatment.

In August 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, made a strategic move by acquiring Turning Point Therapeutics for an undisclosed amount. This acquisition positions Bristol Myers Squibb to address a critical medical need for patients with non-small cell lung cancer testing positive for ROS1. Additionally, it grants access to a pipeline of experimental drugs, including repotrectinib, targeting prevalent mutations associated with oncogenesis. Turning Point Therapeutics, Inc., the acquired company, operates in the targeted therapy sector as a clinical-stage precision oncology company.

Major companies operating in the targeted therapy market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited, ChemGenex Pharmaceuticals Ltd.

North America was the largest region in the targeted therapy market in 2023. The regions covered in the targeted therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Targeted therapy involves small molecule medicines and monoclonal antibodies. Small-molecule medicines are synthetic chemicals inspired by or derived from natural products, distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are used for treating various cancers, including breast cancer, colorectal cancer, leukemia, lung cancer, lymphoma, and renal cancer.

The targeted therapy market research report is one of a series of new reports that provides targeted therapy market statistics, including targeted therapy industry global market size, regional shares, competitors with a targeted therapy market share, detailed targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted therapy industry. This targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The targeted therapy market includes revenues earned by entities by providing various kinds of cancer drugs, such as EGFR inhibitors, angiogenesis inhibitors, and apoptosis inducers. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.